ABUS240517C2000
- 0.90
- 0.000.00%
Arbutus Biopharma Newsroom
Arbutus to Present Imdusiran Data at EASL Congress 2024
WARMINSTER, Pa., May 22, 2024 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (NASDAQ:ABUS) ("Arbutus" or the "Company"), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to
Genevant Sciences And Arbutus Biopharma Win Dismissal Of An Action By Acuitas Therapeutics (Partnered With Pfizer On Vaccine Delivery Systems) Seeking A Declaratory Judgement That The Pfizer Comirnaty Vaccine Does Not Infringe Arbutus Patents
Genevant Sciences And Arbutus Biopharma Win Dismissal Of An Action By Acuitas Therapeutics (Partnered With Pfizer On Vaccine Delivery Systems) Seeking A Declaratory Judgement That The Pfizer Comirnaty
Sector Update: Health Care Stocks Softer Friday Afternoon
Health care stocks eased Friday afternoon with the NYSE Health Care Index down 0.1% and the Health Care Select Sector SPDR Fund (XLV) marginally higher. The iShares Biotechnology ETF (IBB) fell 0.3%.
Arbutus Biopharma Urged to Stop Share Issuances, Explore Alternatives for Hepatitis B Program
Arbutus Biopharma (ABUS) shareholder Whitefort Capital Management issued an open letter to shareholders Friday urging the company to stop further share issuances and explore strategic alternatives for
Express News | Shares of Arbutus Biopharma up 2.4% Premarket After Investor Whitefort Urges Co to Halt Stock Sales, Find Partner
Express News | Whitefort Capital: Calls on Arbutus to Cease Any Further Share Issuances & Plans to Vote Against Proposed Share Increases to Co's Incentive Plan
Express News | Whitefort Capital: Owns About 6.8% of Arbutus Biopharma's Outstanding Shares
Express News | Whitefort Capital: Urges Arbutus Biopharma to Launch a Strategic Review of Its Hepatitis B Virus Portfolio by Yearend
Whitefort Capital Publishes Open Letter to Arbutus Biopharma Shareholders Outlining Paths to Maximize Value
Asserts Arbutus' Share of Patent Infringement Claims Against Moderna and Pfizer/BioNTech is Potentially Worth Billions of Dollars and Preserving that Value Should be a Key Focus Calls on Arbutus to Cease Any Further
Express News | Whitefort Capital Management- Hope to Continue to Work Constructively, Collaboratively With Arbutus Biopharma's Board on These Critical Initiatives
Express News | Whitefort Capital Management- Requested That Arbutus Biopharma's Board Explore All Strategic Options for Hepatitis B Virus (Hbv) Portfolio
Express News | Whitefort Capital Management- Requested That Arbutus Biopharma's Board Immediately Terminate Atm Program
Express News | Whitefort Capital Management-Conveyed Their View to Arbutus Biopharma's Board That Current Market Price of Shares Does Not Reflect Intrinsic Value
Express News | Whitefort Capital Management, LP - Purchased Arbutus Biopharma's Securities Based on Belief That Such Securities, When Purchased, Were Undervalued
Express News | Whitefort Capital Management, LP Reports 6.8% Stake in Arbutus Biopharma Corp as of May 2, 2024 - SEC Filing
Analysts Have Conflicting Sentiments on These Healthcare Companies: Ultragenyx Pharmaceutical (RARE), Hologic (HOLX) and Arbutus Biopharma (ABUS)
Arbutus to Participate in Two Upcoming Investor Conferences
WARMINSTER, Pa., May 07, 2024 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop a fu
The Arbutus Biopharma Corporation (NASDAQ:ABUS) First-Quarter Results Are Out And Analysts Have Published New Forecasts
Last week saw the newest quarterly earnings release from Arbutus Biopharma Corporation (NASDAQ:ABUS), an important milestone in the company's journey to build a stronger business. Revenues fell
Global RNAi Therapeutics Market Insights & Forecasts With Potential Impact of COVID-19 2024-2028 Featuring Sanofi, Alnylam, Arrowhead, Arbutus Biopharma, Benitec Biopharma, Sirnaomics - ResearchAndMarkets.com
DUBLIN--(BUSINESS WIRE)--The "Global RNAi Therapeutics Market (By Molecule Type, Application, End-User & Region): Insights & Forecast with Potential Impact of COVID-19 (2024-2028)" report has been add
Express News | Chardan Capital Reiterates Buy on Arbutus Biopharma, Maintains $4 Price Target